Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia

NCT: NCT03431090 · ACTIVE_NOT_RECRUITING

NCT IDNCT03431090
StatusACTIVE_NOT_RECRUITING
Start Date2018-03-02
Completion2026-12

Brief Summary

This is a Phase I/II study designed to evaluate the kinetics of hematopoietic reconstitution and the incidence of acute chronic GVHD after partially matched related donor hematopoietic cell transplantation using an αβTCR/CD19+ cell depleted graft.

Frequently Asked Questions

What is Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia?

Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia is a clinical trial registered under NCT03431090. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT03431090?

The current status of NCT03431090 (Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia) is: ACTIVE_NOT_RECRUITING.

When did Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia start?

Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia started on 2018-03-02.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑